💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, slow-growing business, reasonably priced.
Aarti Drugs is scored on the pharma / healthcare framework. It keeps a slim 7.6% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.30× reported profit. Free cash flow is worth about 2.0% of its market value.
Over the last 3 years revenue compounded at -2%/yr and profit at 5%/yr. Book value has grown 9%/yr. Return on equity is a healthy 13.6%. In the latest quarter profit fell 9% versus the prior quarter.
At 21× earnings, the stock sits at the 29th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~7%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 17.82 | — | — |
| P/B | 2.42 | 4.1 | better |
| EV/EBITDA | 12.05 | 19.33 | better |
| ROE | 13.61 | — | — |
| ROCE | 13.65 | 14.41 | worse |
| ROA | 7.49 | 1.64 | better |
| Quick Ratio | 1.06 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Negative CAGR — the top line has shrunk over this window. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (5% vs -2%) — margin expansion is at work.
Operating margins have been stable around 8% — no major structural shift.
ROE at 13% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
6% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.3× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 13% above earlier ones.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 54.1% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.